Betta Pharmaceuticals Co.Ltd(300558)
The prior approval opinions of independent directors on matters related to the 29th meeting of the third board of directors are in accordance with the guiding opinions on the establishment of independent director system in listed companies and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of companies listed on GEM issued by China Securities Regulatory Commission Laws and regulations such as Shenzhen Stock Exchange GEM Listing Rules and relevant provisions such as Betta Pharmaceuticals Co.Ltd(300558) (hereinafter referred to as the “company”) independent director working system, in a serious and responsible attitude, based on an independent, prudent and objective position, We listened to the reports of relevant personnel and reviewed relevant materials on the proposal on investment in Wuhan Heyuan Biotechnology Co., Ltd. and related party transactions to be considered at the 29th meeting of the third board of directors. After careful review and discussion, we issued the following prior approval opinions:
We have carefully reviewed the proposal and relevant materials on this connected transaction submitted by the company. This investment is conducive to expanding the company’s new drug innovation technology platform, accelerating the company’s strategic layout in the field of disease treatment, and is in line with the company’s development strategy. It is also understood that Heyuan biology has been in the guidance stage of IPO, the listing audit has been carried out in an all-round way, and the company has also arranged for a third-party due diligence. The valuation of this transaction is based on the R & D characteristics and stage characteristics of innovative drugs in the pharmaceutical industry, combined with the technical advantages and market potential of Heyuan biological product pipeline, and determined through consultation by all parties involved in the capital increase. The pricing follows the market-oriented principle, and there is no situation that damages the interests of the company and shareholders, especially small and medium-sized shareholders. We unanimously agreed to submit the matter to the 29th meeting of the third board of directors for deliberation, and the related directors withdrew from voting in accordance with relevant laws, regulations and the articles of association.
(no text below)
[there is no text on this page, which is the signature page of Betta Pharmaceuticals Co.Ltd(300558) independent directors’ prior approval opinions on matters related to the 29th meeting of the third board of directors] independent directors:
Jiangnan Cai Zhao Jun, Wang Wei, Huang Xinqi March 3, 2022
